Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Johnson and Johnson
Queensland Health
Mallinckrodt
McKesson
Harvard Business School
Cantor Fitzgerald
UBS
Fuji
Colorcon

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,919,373

« Back to Dashboard

Which drugs does patent 6,919,373 protect, and when does it expire?

Patent 6,919,373 protects CONCERTA and is included in one NDA.

Protection for CONCERTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 6,919,373
Title: Methods and devices for providing prolonged drug therapy
Abstract:Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s): Lam; Andrew C. (South San Francisco, CA), Shivanand; Padmaja (Mountain View, CA), Ayer; Atul D. (Palo Alto, CA), Weyers; Richard G. (Los Altos, CA), Gupta; Suneel K. (Sunnyvale, CA), Guinta; Diane R. (Palo Alto, CA), Christopher; Carol A. (Belmont, CA), Saks; Samuel R. (Burlingame, CA), Hamel; Lawrence G. (Mountain View, CA), Wright; Jeri D. (Dublin, CA), Hatamkhany; Zahedeh (San Jose, CA)
Assignee: Alza Corporation (Mountain View, CA)
Application Number:09/253,317
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 6,919,373

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-001 Aug 1, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-004 Apr 1, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-002 Aug 1, 2000 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Pharms CONCERTA methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 021121-003 Dec 8, 2000 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Novartis
Chinese Patent Office
Covington
Queensland Health
Accenture
Baxter
US Army
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot